biotech / news / / Reuters
Boehringer Ingelheim's zongertinib is approved as a first-line treatment for a rare form of non-small cell lung cancer.
The FDA approved Boehringer Ingelheim's zongertinib as a first-line NSCLC treatment targeting rare mutations.
KEY POINTS
- Zongertinib's first-line approval could double Boehringer's addressable lung cancer market.
- The FDA cleared Hernexeos under the National Priority Voucher Program, processing the application in 44 days.
- In trials, zongertinib shrank tumors in 76% of untreated patients versus 30%-45% for current therapies.
COMPANIES
Summarized by Newsio from Reuters. How we summarize →